▶ The PolicyIQ framework · v2 (six channels) click to expand — revised taxonomy: six channels, elections folded into institutional risk, enforcement intensity as meta-attribute

PolicyIQ treats policy as a measurable signal stream with a taxonomy, maturity model, materiality score, and dispersion measure, organized into a three-level architecture. This is the v2 taxonomy — revised after stress-testing the original six against semis, pharma, and banks. Key changes from v1: regulatory has been split into sanctions/export controls (separated from trade) and competition/sectoral regulation (merged with antitrust and digital governance); monetary/FX has been folded into a new institutional & political risk channel that also absorbs elections (now treated as a velocity modifier rather than a standalone type) and enforcement intensity (a meta-attribute on every signal).

Six channels · v2 taxonomy

Each channel has a distinct transmission mechanism and a distinct set of firm-attribute dependencies. Most signals carry one primary channel and one or two secondary channels.

Kinetic & geopolitical — active conflict, military-origin sanctions, trade-route disruption
Trade & market access — tariffs, quotas, NTBs, trade agreements, customs enforcement
Sanctions & export controls — entity lists, FDPR, technology licenses, secondary sanctions
Fiscal & industrial policy — tax credits, subsidies, procurement, industrial strategy, R&D funding
Competition & sectoral regulation — antitrust, agency rulemaking (FDA/FERC/FCC), product standards, IP, digital governance
Institutional & political risk — central bank independence, elections as velocity modifier, enforcement intensity, executive intervention propensity, rule-of-law

What v2 fixes

v1's "regulatory" bucket was doing too much work — antitrust, sector rules, product standards, and digital governance have meaningfully different transmission mechanisms even if they share an agency-rulemaking shell. v1's "monetary/FX" double-counted what sell-side macro already covers and missed the political dimension entirely. v1's "elections" channel was a category error — elections don't directly hit P&L, they change the velocity and enforcement of signals across other channels. The v2 fix is to make institutional & political risk a real channel covering Fed independence, executive intervention propensity, and rule-of-law degradation, with elections folded in as a velocity modifier and enforcement intensity as a meta-attribute on every signal.

Maturity spectrum · five stages

Signals progress through Rumor → Proposal → Imminent → Enacted → Implemented. Each transition is a discrete re-pricing event. Velocity matters more than the current stage — markets price levels accurately and velocity inaccurately. Signals regressing from Enacted back to Proposal (SCOTUS IEEPA ruling, SEC climate disclosure stay) are often more actionable than new signals at Proposal because regression events are rare and under-modeled.

Materiality × dispersion

Materiality = share of 12-month forward return variance an industry attributes to policy (HIGH >35%, MED 15–35%, LOW <15%; currently judgment-based, v2 will be quantitative). Dispersion = fraction of impact accruing as cross-sectional reshuffling within the industry vs. as a common sector direction (0 = pure sector trade; 1 = pure pair trade). High-materiality × high-dispersion industries are where policy-aware analysis is most valuable and most under-weighted by peer processes.

Three-level architecture

L1 (cross-sector) answers "where to look" across all 74 GICS L3 industries. L2 (this view) answers "what's happening in this industry" via cross-signal interaction, firm-attribute matrix, and aggregate Porter rolled up from per-signal Porter decompositions. L3 (per-signal) answers "how do I trade this specific signal" via transmission chain, scenario grid, and concrete company trade expressions. Each level is independently consumable but the value compounds when used together.

Sector regime · pharmaceuticals · April 2026

Multi-channel compression: tariffs × pricing × supply chain decoupling × enforcement uncertainty

Pharmaceuticals is the most multi-channel-exposed industry in the framework — five of six channels are active simultaneously, only kinetic/geopolitical is dormant. The dominant signal is the Section 232 100% pharma tariff (imminent, Q1 2026 announcement, implementation expected Q2–Q3) which creates discontinuous cost shock for any company with non-US final manufacturing. Layered on top: IRA Medicare Part D negotiation Round 2 (15 additional drugs, list to be announced Feb 2027 covering CY 2028), the IRA small-molecule penalty (9-year vs 13-year exclusivity) which creates a structural modality preference toward biologics, BIOSECURE Act enforcement constraining Chinese API and CRO supply, NIH funding cuts impacting early-stage discovery, and the RFK Jr.-led HHS posture creating enforcement-intensity uncertainty across FDA, CDC, and CMS. The compound effect is severe firm-level dispersion (0.72) because the firm attributes that determine exposure to each channel are largely orthogonal to each other — a company can be insulated from one channel and severely exposed to another, and no single firm is well-positioned across all five active channels. This is the framework's clearest example of how multi-channel exposure creates pair-trade rather than sector-trade opportunity.

Sector context · YTD 2026

XLV YTD−9.2%

XPH YTD−14.8%

vs S&P 500−10.1%

Fwd P/E13.2×

5yr avg P/E16.5×

Implied vol34.2

MaterialityHIGH

Dispersion0.72

Channels live5 / 6

Top 10 disp.22pp

L1 position context where pharma sits in cross-sector view

Pharma sits firmly in the L1 target zone — high materiality combined with the framework's third-highest dispersion reading at 0.72, behind only Semiconductors (0.78) and Oil & Gas (0.70 but with kinetic exposure). Within the Health Care GICS L1 sector, pharma is the highest-dispersion industry; biotech sits adjacent at 0.62 with overlapping but distinct firm-attribute exposures.

The L1 ranking has pharma at position #3 by dispersion among HIGH-materiality industries. Three quarters ago (the May 2024 cutoff) pharma sat at 0.55 dispersion with materiality MED — the move to HIGH materiality and 0.72 dispersion in 18 months reflects the addition of Section 232 100% as a new dominant signal and the extension of IRA Part D pricing into a second negotiation round.

This L2 view exists because pharma cleared two L1 thresholds simultaneously: materiality HIGH (justifying specialized analysis at all) and dispersion above 0.65 (justifying firm-attribute work because the trade is pair-style not directional). Industries that clear only one threshold don't get an L2 build under the current framework's prioritization rules.

Active signal inventory · nine signals across five channels live

Section 232 100% pharmaceutical tariff

IMMINENT

Trade & market access Institutional risk

Discontinuous shock announced Q1 2026 covering all patented pharmaceutical imports. Implementation framework still under negotiation but a 100% tariff on imports of branded pharmaceuticals from any country without a US manufacturing equivalent is the working baseline. Firm exposure axis: final-product manufacturing footprint geography. Ireland-based final assembly is the maximum-exposure case; US-domestic final manufacturing is the maximum-insulation case.

Velocity: acceleratingEnforcement: high (executive priority)

L3 Signal Deep Dive

IRA Medicare Part D negotiation Round 2

IMPLEMENTED

Fiscal & industrial Comp. & sectoral reg

Round 1 prices took effect Jan 2026 for the initial 10 drugs (Eliquis, Xarelto, Januvia, Jardiance, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, Fiasp/NovoLog). Round 2 selection of 15 additional drugs to be announced February 2027 covering CY 2028 prices. Round 2 exposure is highest for companies with concentrated Part D revenue in eligible drug classes (anticoagulants, oncology, immunology, diabetes). Firm exposure axis: Part D revenue concentration in eligible classes.

Velocity: stableEnforcement: high (statutory)

IRA small-molecule exclusivity penalty (9yr vs 13yr)

IMPLEMENTED

Fiscal & industrial Comp. & sectoral reg

Small molecules become eligible for Medicare price negotiation 9 years post-approval; biologics get 13 years. Creates a structural 4-year revenue cliff differential favoring biologics, with the biggest impact on companies whose late-stage pipelines are small-molecule heavy. Already reshaping R&D capital allocation across the sector. PBMs are absorbing some impact via formulary changes that favor biologics earlier than they otherwise would.

Velocity: stableEnforcement: high (statutory)

BIOSECURE Act · China API and CRO restrictions

ENACTED

Sanctions & export ctrl Trade & market access

Restricts US federal contracting and Medicare/Medicaid reimbursement for products developed using services from named Chinese biotech firms (WuXi Biologics, WuXi AppTec, BGI, MGI, Complete Genomics). Compliance grace period extended through end-2027 for legacy contracts. Firm exposure axis: China CRO/CDMO dependency in active programs. Companies with US/European-only supply chains insulated; companies with WuXi-routed manufacturing or development face mandatory transition costs.

Velocity: acceleratingEnforcement: medium-high

NIH funding cuts · FY2026 appropriations

IMPLEMENTED

Fiscal & industrial Comp. & sectoral reg

~22% reduction in NIH extramural research funding compared to FY2024 baseline. Direct effects on academic discovery pipelines feed indirectly into pharma in-licensing economics; biotech valuations have compressed significantly which reduces in-licensing costs but also signals fewer promising assets. Net effect on large-cap pharma is small but cumulative; the bigger effect is on biotech business development pricing.

Velocity: regressing (statute under review)Enforcement: low (impoundment disputes)

RFK Jr. HHS posture · FDA / CDC / CMS leadership

ENACTED

Institutional risk Comp. & sectoral reg

RFK Jr. confirmed as HHS Secretary creates enforcement-intensity uncertainty across FDA approvals (vaccines, mRNA platforms), CMS coverage decisions, and CDC recommendations. The signal is not a specific rule change but a broad shift in agency disposition. Vaccines manufacturers face the highest enforcement-intensity downside; companies with non-vaccine pipelines and traditional small-molecule chemistry less affected. The ACIP membership reshuffle in March 2026 confirmed this is operative not rhetorical.

Velocity: acceleratingEnforcement: high (active intervention)

FTC patent thicket & "product hopping" enforcement

ENACTED

Comp. & sectoral reg

FTC continued enforcement against Orange Book patent listings deemed improper and against "product hopping" strategies that delay generic/biosimilar entry. Multiple consent decrees in 2025–26. Affects companies with significant biosimilar-defendant exposure on legacy biologics where lifecycle management strategies are now constrained. AbbVie/Humira is the canonical case; similar dynamics emerging for Stelara and Eylea.

Velocity: stableEnforcement: medium-high

PBM reform · rebate transparency & spread pricing

PROPOSAL

Comp. & sectoral reg Fiscal & industrial

Bipartisan PBM reform package working through Senate Finance with House Energy & Commerce companion. Would mandate rebate pass-through, prohibit spread pricing in Medicare, and require PBM transparency reporting. Implementation if enacted is 2027 at earliest. Net pharma effect is ambiguous — eliminating rebate inflation would lower list prices but also lower the value of formulary placement bargaining; companies most exposed are those with high-rebate drugs in competitive classes.

Velocity: acceleratingEnforcement: pending statutory

340B reform · ceiling price disputes & eligibility

PROPOSAL

Comp. & sectoral reg Fiscal & industrial

Multiple federal court rulings in 2025 sided with manufacturers on contract pharmacy restrictions; HRSA appeals pending. Bipartisan reform proposals would tighten covered entity eligibility and limit duplicate discounts. Impact concentration is on hospital-channel oncology and specialty drugs; oral oncology and biologics with high contract pharmacy diversion most affected. Stable signal but legal velocity is high.

Velocity: accelerating (litigation)Enforcement: contested

Firm attribute matrix · 12 companies × 8 attributes L2 canonical object

The firm attribute matrix is the analytical scaffold that converts the channel taxonomy into company-level differential exposure. Each row is a large-cap pharma; each column is an attribute that determines exposure to one or more channels. Cell color = exposure intensity from green (insulated/positive) through gray (neutral) to red (severely exposed). The matrix is designed to be read column-wise (which channel does this attribute drive?) and row-wise (which company is differentially exposed across the full attribute set?). The bottom of this section rolls these attribute exposures up into per-channel scores so you can see at a glance which firms are concentrated in which channel, and which firms have the rare property of being insulated across all five active channels simultaneously — the framework's relative-winner candidates.

Company	US mfgfinal-product footprint	ModalitySM vs biologic mix	Part D% revenue exposed	IRA R1drugs in Round 1	China dep.CRO/API/CDMO	Vax/mRNARFK Jr. exposure	Biosim def.FTC/litigation	IP cliff5yr revenue at risk
LLYEli LillyIndianapolis dominant · GLP-1 leader	~85%	Mixed	Low	0	Low	Low	Low	~15%
GILDGilead SciencesUS dominant · HIV antiviral franchise	~80%	SM-heavy	Low	0	Low	Low	Low	~28%
VRTXVertex PharmaBoston · CF rare disease franchise	~85%	SM-heavy	Low	0	Low	Low	Low	~25%
AMGNAmgenThousand Oaks · biologic-only	~70%	Biologic	Med	1 (Enbrel)	Low	Low	Med	~38%
REGNRegeneronTarrytown · Eylea franchise	~80%	Biologic	Med	0	Low	Low	High	~45%
MRKMerckRahway · Keytruda franchise	~65%	Biologic	Med	1 (Januvia)	Low	Mod	Low	~55%
PFEPfizerNYC · mixed US/Ireland/Belgium	~50%	Mixed	Med	1 (Eliquis*)	Low	High	Low	~50%
BMYBristol Myers SquibbNJ · Eliquis + Opdivo concentration	~55%	Mixed	High	2 (Eliquis, Pomalyst)	Low	Low	Low	~60%
ABBVAbbVieNorth Chicago · PR mfg · post-Humira	~60%	Biologic	Med-hi	1 (Imbruvica)	Low	Low	High	~35%
JNJJohnson & JohnsonNJ · Belgium/Switzerland exposure	~50%	Biologic	Med-hi	2 (Stelara, Xarelto*)	Low	Med	High	~40%
AZNAstraZenecaUK · Sweden · significant China presence	~25%	Biologic	Med	1 (Farxiga)	Med	Med	Low	~35%
NVSNovartisBasel · Switzerland mfg dominant	~20%	Biologic	Med	1 (Entresto)	Low	Low	Low	~32%

Exposure intensity: Insulated / positive Light positive Neutral Moderate exposure Significant exposure Severe exposure

Sort note: rows are ordered by aggregate cross-attribute exposure (least to most), so LLY at top is the framework's lowest-exposure large-cap and NVS at bottom is the highest. Eliquis* and Xarelto* shared between PFE/BMY and BMY/JNJ respectively per partnership economics. Methodology: attribute classifications drawn from 10-K segment disclosure, manufacturing facility filings, CMS Round 1 selection, FDA/EMA approval databases, and FTC consent decree records as of April 2026. Limits: US manufacturing percentages are point-in-time estimates of final-product assembly footprint; companies are actively reshoring under Section 232 pressure so these will move materially over 12–18 months. Part D exposure is approximated from 10-K disclosed Medicare revenue concentration and is necessarily imprecise. IP cliff figures reflect publicly disclosed LOE exposure within the 5-year window and exclude probability-weighted pipeline replacement.

Channel rollup — firm exposure scored across the five active channels. Each cell aggregates the relevant attributes from the matrix above into a single channel-level exposure score. The right-most column is a simple unweighted total (cap of 25 = severe across all 5). Read this table to identify single-channel concentrations (a firm with one red cell and four green/neutral cells has a clean L3 trade) vs. multi-channel compression (a firm with multiple red cells has compounding negative exposure with no offsetting positive).

Company	2TradeSection 232 100%	3SanctionsBIOSECURE	4FiscalIRA Part D + SM penalty	5Comp/RegFTC, PBM, biosim	6Inst. riskRFK Jr. HHS	Totalunweighted (25 max)
LLYEli Lilly	1	1	2	2	1	7
GILDGilead	1	1	2	2	1	7
VRTXVertex	1	1	3	2	1	8
AMGNAmgen	2	1	4	3	1	11
REGNRegeneron	1	1	3	5	1	11
MRKMerck	3	1	4	2	4	14
PFEPfizer	4	2	4	2	5	17
ABBVAbbVie	3	1	4	5	2	15
BMYBristol Myers	3	1	5	2	2	13
JNJJohnson & Johnson	4	1	5	5	3	18
AZNAstraZeneca	5	4	4	2	3	18
NVSNovartis	5	1	4	2	2	14

Reading the rollup: three relative-winner candidates emerge with totals of 7–8 (LLY, GILD, VRTX) — all share the property of US-dominant manufacturing combined with low Part D exposure and no Round 1 hits. Three multi-channel compression cases at the bottom (JNJ, AZN, PFE) score 17–18, but for very different reasons: JNJ is Comp/Reg-heavy via Stelara biosimilar plus fiscal via two Round 1 drugs; AZN is uniquely Trade-and-Sanctions heavy due to UK/Sweden manufacturing combined with material China operations; PFE is Institutional-risk-heavy due to vaccine/mRNA franchise plus split fiscal/trade exposure. The five firms in the middle (AMGN, REGN, MRK, BMY, ABBV) all have one or two channel-specific concentrations rather than across-the-board exposure, which makes them the cleanest candidates for L3 single-channel deep dives. The framework's headline insight: there is no firm with severe exposure across all five channels, and there is no firm with insulation across all five. Cross-channel diversification is the dominant feature of the sector, which is precisely what makes this a pair-trade environment rather than a sector trade.

Cross-signal interaction graph · how the nine signals compound at the P&L level

Most peer analyses treat the nine pharma signals as additive — each one moves earnings by some amount, sum the impacts, done. The framework's claim is that several pairs and triples of signals interact non-additively: they affect the same firm attribute from different angles, or they create discontinuous regime shifts that aren't visible from individual signal analysis. The graph below shows the dominant interaction pathways. Read it as: signals on the left feed into intermediate firm-attribute nodes in the middle, which feed into the four P&L outcome nodes on the right. Where multiple signal arrows converge on the same intermediate node, that's a compounding interaction.

Key compounding pathways: (1) Section 232 + BIOSECURE both hit final-product manufacturing geography from different angles, so a company forced to reshore for tariff reasons may simultaneously face supply-chain rerouting for sanctions reasons — capex stacking. (2) IRA Part D Round 2 + 340B reform + PBM reform all converge on the channel-mix node, creating an ambiguous net effect that depends on each company's specific channel mix. (3) IRA SM penalty + BIOSECURE both reshape the in-licensing/BD pipeline (the SM penalty reduces small-molecule asset value, BIOSECURE eliminates certain CRO routes), so future pipeline economics for the whole industry are shifting at the same time. (4) RFK Jr. HHS posture + FTC patent enforcement both flow into multiple compression / re-rate via uncertainty rather than via direct P&L — this is the channel that explains why the sector is trading at 13.2x forward vs 16.5x historical average.

Aggregate Porter view · how the nine signals shift the five forces for pharmaceuticals

↑ Force 1 of 5

Buyer power

Increasing materially. CMS via IRA negotiation has become an active price-setter rather than a passive payer; PBM reform if enacted would consolidate buyer-side leverage further; 340B litigation outcomes could either expand or constrain hospital buyer power. Net effect: buyer side has gained structural pricing power for the first time in pharma's modern history.

Drivers: IRA Part D R1+R2 · PBM reform · 340B

↑ Force 2 of 5

Supplier power

Increasing in supply chain. Section 232 raises the cost of imported APIs and finished doses, BIOSECURE eliminates the lowest-cost CRO/CDMO option (China), and reshoring increases the bargaining power of US-based contract manufacturers in the short-medium term. NIH cuts indirectly raise upstream discovery input costs.

Drivers: 232 · BIOSECURE · NIH cuts

↔ Force 3 of 5

Threat of new entrants

Mixed. NIH cuts and biotech valuation compression reduce the rate of new entrants; but FTC patent enforcement and biosimilar pathway facilitation lower the barriers for biosimilar entrants specifically. Net effect roughly neutral but the composition of new entrants has shifted from novel-asset biotechs toward biosimilar developers.

Drivers: NIH · FTC · biosim pathway

↑ Force 4 of 5

Substitute threat

Increasing. Biosimilar entry is being accelerated by FTC enforcement against patent thickets and product hopping; the IRA SM penalty makes biosimilars relatively more attractive in formulary placement timing; 340B and PBM reforms could change the economics of formulary preference for substitutes vs. originators.

Drivers: FTC · IRA SM · PBM reform

↑ Force 5 of 5

Internal rivalry

Increasing on differentiated firm exposure. Because the five active channels create such different exposure profiles across companies, competitive dynamics are now firm-specific rather than category-wide. Companies with US manufacturing + biologic-heavy portfolios + low Part D exposure are gaining relative position vs companies on the wrong side of any of those attributes.

Drivers: cross-channel attribute heterogeneity

Synthesis · relative winners, mid-pack, and compression cases framework calls

Relative winners · insulated across channels

LLY GILD VRTX

Eli Lilly is the cleanest framework call: ~85% US final manufacturing footprint (Indianapolis + North Carolina expansion), no Round 1 IRA hits, GLP-1 franchise that is overwhelmingly commercial-channel rather than Medicare Part D, low vaccine/mRNA exposure, low China supply chain dependency, and the most pricing power in the sector via Mounjaro/Zepbound demand. The framework's only cautions on LLY are the SM-vs-biologic ambiguity for GLP-1s (peptides classified as biologics under IRA, which works in LLY's favor) and the eventual Mounjaro IP cliff in the early 2030s.

Gilead wins via similar mechanics: US manufacturing concentration, HIV antiviral franchise that runs through commercial and 340B channels rather than Part D, and zero Round 1 IRA exposure. The flag is small-molecule modality which exposes future products to the 9-year IRA penalty — less an issue for Biktarvy (commercial) but relevant for the oncology pipeline.

Vertex is the rare-disease structural winner: CF franchise sits outside the IRA negotiation universe, US manufacturing, low channel-mix complexity. The asymmetric upside is the casgevy gene therapy franchise; the asymmetric downside is small-molecule modality classification on the pain pipeline.

Mid-pack · single-channel concentrations (clean L3 candidates)

AMGN REGN MRK BMY ABBV

These five firms each have one or two channel-specific concentrations rather than across-the-board exposure, which makes them the cleanest candidates for L3 single-channel deep dives. AMGN is fiscal-concentrated via Enbrel; REGN is comp/reg-concentrated via Eylea biosimilar litigation; MRK is fiscal-and-institutional concentrated via Januvia + Keytruda upcoming + vaccine franchise; BMY is fiscal-concentrated via the Eliquis cliff which is the biggest single Round 1 hit in the sector; ABBV is comp/reg-concentrated via the FTC posture toward Humira-style lifecycle defense.

The framework call is to wait for L3 trades on each of these rather than treat them as composite long/short positions — the single-channel exposure creates concentrated event-risk around specific signal transitions (CMS announcements, court rulings, ACIP meetings) that can be targeted directly with options structures.

Compression cases · multi-channel exposure

JNJ AZN PFE NVS

Johnson & Johnson is the framework's worst-positioned US-domiciled large-cap: Stelara biosimilar erosion is now active (comp/reg severe), two Round 1 IRA hits (fiscal severe), Belgium/Switzerland manufacturing footprint creates Section 232 exposure, and the medtech business doesn't offset because medtech is itself exposed to a different set of policy signals.

AstraZeneca has the framework's most distinctive exposure profile: it is the only large-cap with simultaneously high Trade exposure (UK/Sweden mfg), Sanctions exposure (material China operations), and Fiscal exposure (Farxiga Round 1). The compounding effect is severe even though no individual channel is at the maximum.

Pfizer compresses on a different vector: vaccine and mRNA franchise concentration creates the framework's highest Institutional risk score via RFK Jr. HHS posture, layered on top of split US/Ireland manufacturing (Trade) and Eliquis IRA exposure (Fiscal). PFE's saving grace is Paxlovid which provides a near-term cash flow buffer but doesn't change the structural picture.

Novartis is the cleanest Section 232 short: Switzerland-based final manufacturing means the company faces the maximum trade-channel exposure, with no compensating advantage on the other channels. Entresto Round 1 + Switzerland mfg makes this the most concentrated single-channel compression case in the sector.

Priced in vs. to be priced in where the framework's edge is

Largely priced in (April 2026)

IRA Round 1 prices took effect Jan 2026; sell-side models have largely incorporated the per-drug effects. Eliquis, Januvia, Stelara revenue impacts visible in BMY, MRK, JNJ consensus.
Section 232 100% pharma announcement was Q1 2026; the headline tariff number is in consensus. What's not in consensus is the implementation framework details (carve-outs, phasing, country-specific terms) and the reshoring capex response timeline.
Humira biosimilar erosion has been priced into ABBV for over two years; current valuation reflects realistic assumptions about Skyrizi/Rinvoq replacement.
BIOSECURE Act grace period through 2027 means near-term P&L impact is minimal and the market has discounted the eventual transition costs.
Sector multiple compression from 16.5x to 13.2x forward is itself a partial pricing of cumulative policy uncertainty — the question is whether 13.2x reflects all of it or just some of it.

To be priced in · framework alpha sources

IRA Part D Round 2 selection (Feb 2027) is not in consensus drug-by-drug because the selection criteria leave room for surprise on which drugs make the cut. Companies with multiple eligible drugs are systematically under-discounted.
Section 232 implementation framework details — whether reshoring credits offset tariff costs, whether transfer-pricing adjustments are permitted, whether bilateral carve-outs (UK, Switzerland, Ireland) emerge — will create large per-firm dispersion that consensus has not modeled because consensus has used a single tariff rate.
RFK Jr. HHS enforcement intensity on vaccines is being priced as low-probability tail risk; the framework view is that the probability of disruptive enforcement decisions on ACIP recommendations and FDA approval pathways is meaningfully higher than implied vol suggests.
FTC patent thicket enforcement outcomes for Stelara and Eylea are not yet priced — consensus assumes the Humira pattern (gradual erosion over 4–5 years) but the FTC is now actively shortening that timeline.
The relative-winner trade (long LLY/GILD/VRTX vs short JNJ/NVS/AZN) has not been crowded into — the spread between relative-winner and compression-case forward multiples is currently ~3 turns, vs. a fundamental gap that the framework estimates closer to 5–6 turns.
Cross-signal interaction effects (capex stacking from 232 + BIOSECURE, channel-mix ambiguity from IRA + 340B + PBM) are not modeled at all by single-signal sell-side analyses.

Signposts · calendar of upcoming maturity transitions to monitor

Q2 2026

Section 232 implementation framework — expected announcement of phasing, country carve-outs, and reshoring credit mechanism. Highest single signal velocity event for the next 90 days.

Q2–Q3 2026

FDA leadership decisions under RFK Jr. — pending approval calendar includes several mRNA and vaccine assets where enforcement-intensity risk is elevated. Watch ACIP meeting outcomes specifically.

Jun 2026

FTC enforcement actions on Stelara biosimilar entry — multiple consent decree negotiations active. Outcomes will set the template for Eylea, Keytruda lifecycle defense.

Q3 2026

PBM reform Senate Finance markup — the package is moving but timing is the question. A Q3 markup would put implementation in 2027; slippage to 2027 markup pushes implementation to 2028.

Sep 2026

340B Supreme Court petition decision — HRSA has petitioned for cert on contract pharmacy ruling; cert grant or denial materially shifts the timeline for resolution.

Feb 2027

IRA Round 2 drug selection announcement — CMS will publish the 15 additional drugs subject to negotiation for CY 2028 prices. The single highest-impact known calendar event for the sector.

L2 Pharmaceuticals build · April 8 2026. First L2 view built using the v2 six-channel taxonomy. The firm attribute matrix is included as a first-class output rather than as a backstage scaffold — the design rationale is that the matrix is what makes the framework's logic transparent and stress-testable, and a user looking at the synthesis cards should be able to trace any winner/loser call back to specific cells in the matrix.

What this build validates about the framework. Pharma was the right test case because it spans five of six channels and has natural firm-attribute heterogeneity. The matrix successfully separates relative winners (LLY/GILD/VRTX) from compression cases (JNJ/AZN/PFE/NVS) with a clear underlying logic that doesn't reduce to a single channel. The cross-signal interaction graph identifies genuine compounding pathways (Section 232 + BIOSECURE both hitting manufacturing geography, IRA + PBM + 340B all hitting channel mix) that single-signal analyses miss.

What this build flags about the framework. (1) The "institutional & political risk" channel is concentrated almost entirely in PFE and MRK via vaccine/mRNA exposure to RFK Jr.; if we ran the same exercise on banks or media we'd see a much broader institutional risk distribution — which suggests the channel's apparent narrowness here is sector-specific rather than a taxonomy problem. (2) The boundary between fiscal (IRA pricing) and comp/reg (PBM, 340B) is fuzzy in pharma because both end up affecting net realized price. The framework's approach of dual-tagging signals (primary + secondary channels) is what makes this manageable. (3) The matrix is heavy with judgment-based attribute classifications; v2 of the build should ground each attribute in specific 10-K disclosures so the framework is auditable.

Methodology & limits. All signal classifications, materiality estimates, dispersion ratios, and firm exposure scores are analyst judgment rather than quantitative model output. Manufacturing footprint percentages are point-in-time estimates that will move materially as Section 232 reshoring proceeds. The relative-winner / compression-case framing should be tested against forward returns over the next 6–12 months as a validation of the framework's L2 methodology.

Next steps. Build L3 deep-dives for the highest-velocity signals: Section 232 implementation framework (when details emerge), IRA Round 2 selection (when CMS announces), and FTC patent thicket enforcement on Stelara (when the consent decree pattern resolves). Apply the same L2 build pattern to Semis (highest-dispersion industry) and Oil & Gas (highest-materiality industry) to test whether the v2 taxonomy works as well outside pharma.